Does Semaglutide Increase Oestrogen Levels?

What the licensed trial data actually measured, and what it did not

The STEP 1 trial, published in the New England Journal of Medicine, ran 68 weeks with 1,961 adults using semaglutide 2.4mg weekly. Participants lost an average of around 15% of body weight. The primary endpoints were weight, cardiometabolic markers and safety, not oestrogen levels. No systematic measurement of oestrogen was built into the trial design, which means STEP 1 neither confirms nor rules out a direct hormonal effect; it simply was not measuring for one.

What researchers do observe across obesity medicine studies broadly is that weight reduction correlates with changes in circulating sex hormones. In people with overweight or obesity, adipose tissue (body fat) converts androgens into oestrogens via an enzyme called aromatase. More fat tissue generally means more of this conversion occurring. As fat mass falls, that background conversion rate falls with it. The result can be lower total oestrogen in some individuals and, in women with very high starting levels linked to excess adiposity, a more balanced hormonal profile after weight loss. Neither effect is unique to semaglutide; it appears with other effective weight-loss interventions too.

The NHS semaglutide medicines page lists the known side effects of Wegovy. Hormone changes are not among them. That is consistent with a medicine whose receptor targets sit in the gut, the pancreas, and appetite centres of the brain, not in the ovaries or adrenal glands.

Contraception and HRT: where the clinical guidance is specific

There is one area where semaglutide and hormones do intersect in a documented, guidance-level way, and it is worth being precise about it. NHS England's guidance on weight-management injections advises clinicians to discuss contraception with anyone of reproductive age starting these medicines. For semaglutide specifically, the concern is not that it raises or lowers oestrogen, but that rapid early weight loss can affect the regularity of menstrual cycles, which can create uncertainty about contraceptive reliability if someone was using calendar methods.

There is also a practical point about oral contraceptives: semaglutide slows gastric emptying, meaning food and medicines spend longer in the stomach before reaching the small intestine. The extent to which this affects oral contraceptive absorption has not been definitively quantified for semaglutide, though the guidance encourages a conversation with your prescriber. For tirzepatide (Mounjaro), there is specific guidance to add a non-oral backup method during early treatment weeks; NHS England's advice for semaglutide is more broadly framed as a discussion rather than a categorical instruction.

On HRT: NHS England notes that transdermal forms (patches and gels) sidestep any absorption questions entirely, since they deliver hormone through the skin rather than the gut. If you are on oral HRT and starting semaglutide, that is a practical conversation to have with your prescriber before your first pen. You can read about the full dosing schedule for Wegovy on our Wegovy doses page.

Menstrual cycle changes reported during weight loss treatment

Some women do notice changes to their period after starting semaglutide, cycles may become more regular, irregular, lighter or, occasionally, more noticeable. Understanding why requires separating several things that can all be happening at once.

First, meaningful fat loss in itself affects the hormonal axis that governs menstruation (the hypothalamic-pituitary-ovarian axis). Women with polycystic ovary syndrome (PCOS), for example, often see cycle changes after weight loss, as reduced adiposity can lower insulin resistance and alter androgen-to-oestrogen ratios. That is a body-composition effect, not a semaglutide effect per se.

Second, the early weeks of treatment can involve reduced caloric intake, nausea and digestive disruption, all of which can affect cycle timing through stress signals, regardless of what medicine is involved. If you are tracking doses alongside symptoms, a clear account of the Wegovy dose escalation schedule may help you separate timing effects from dose effects when you report back to your prescriber.

Third, for anyone who was previously using oral contraception primarily for cycle regulation rather than contraception, a change in cycle pattern after starting semaglutide is not automatically a sign that the contraception has stopped working. It may simply reflect the effect of weight change on the underlying hormonal pattern. Report it; do not assume either way.

The honest answer is that current evidence does not allow us to say semaglutide reliably changes oestrogen by a predictable amount in a predictable direction. Individual variation (starting weight, rate of loss, baseline hormonal status) matters enormously, and if you want to understand how the treatment steps up over time, our page covering Wegovy mg levels explains what each stage of the schedule looks like. If you are weighing up treatment and hormonal considerations are a significant factor, a structured consultation is the right place to work through them, and our guide on how to increase dose of semaglutide outlines what that progression involves and when it is appropriate to move up. Our clinical team reviews each consultation individually, and questions about contraception or HRT are a normal and expected part of that conversation.

For broader context on what Wegovy involves before and during treatment, the Wegovy overview page covers the licensed indications, eligibility criteria and what private treatment includes. If cost is a factor in your thinking, our Wegovy price comparison page explains what private prescriptions typically cover in the UK and what makes prices differ between providers. When you are ready to ask these questions with a prescriber rather than a search engine, you can speak to our prescribers via a free consultation.